SCHEMBL25801709

SCHEMBL25801709

CCCCCCCCc1cnc(CCl)cn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.47
ALDH1A1 P00352 3/20 0.41
TSHR P16473 1/20 0.41
CYP19A1 P11511 3/20 0.37
MAPT P10636 3/20 0.37
RAB9A P51151 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
USP2 O75604 1/20 0.37
GAA P10253 1/20 0.37
HPGD P15428 1/20 0.37
KMT2A Q03164 1/20 0.37
HSD17B10 Q99714 1/20 0.37
TDP1 Q9NUW8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
THRA P10827 1/20 0.35
THRB P10828 1/20 0.35
NPC1 O15118 1/20 0.35
STAT3 P40763 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27602441 0.92 GABRP (0.40) KCNH2ALDH1A1TSHRMAPTRAB9A
SCHEMBL27329523 0.89 KCNH2 (0.56) KCNH2ALDH1A1TSHRMAPTRAB9A
SCHEMBL5436769 0.87 KCNH2 (0.52) KCNH2ALDH1A1MAPTRAB9ASMN1; SMN2
SCHEMBL12829587 0.83 KCNH2 (0.50) KCNH2ALDH1A1MAPTRAB9ASMN1; SMN2
SCHEMBL27731599 0.83 KCNH2 (0.48) KCNH2ALDH1A1MAPTRAB9ASMN1; SMN2
SCHEMBL27698233 0.81 KCNH2 (0.47) KCNH2ALDH1A1MAPTRAB9ASMN1; SMN2
SCHEMBL19309229 0.80 KCNH2 (0.47) KCNH2ALDH1A1MAPTRAB9ASMN1; SMN2
SCHEMBL22341560 0.80 KCNH2 (0.47) KCNH2ALDH1A1MAPTRAB9ASMN1; SMN2
SCHEMBL4685973 0.80 KCNH2 (0.47) KCNH2ALDH1A1MAPTRAB9ASMN1; SMN2
SCHEMBL19309236 0.78 KCNH2 (0.46) KCNH2ALDH1A1MAPTRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4081511-B3 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES SITRYX THERAPEUTICS LTD (GB) 2026-03-04 EP disclosed
EP-4442319-A2 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES Sitryx Therapeutics Limited (GB) 2024-10-09 EP disclosed
EP-4081511-B1 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES SITRYX THERAPEUTICS LTD (GB) 2024-07-31 EP disclosed
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2023-07-13 US disclosed
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES CPA2, RO60, C5AR1 KCNH2 4192/4885ALDH1A1 134/4885TSHR 3550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.